AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02352948
Drug: MEDI4736 (durvalumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 (durvalumab) treatment by intravenous infusion
Trial: NCT00354874
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT00354874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01781572
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 will be administered orally once daily
Trial: NCT01781572
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 will be administered orally twice daily
Trial: NCT02289300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Trial: NCT02289300
Drug: DCB-BO1202+Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)
Trial: NCT01325168
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Trial: NCT04094727
Drug: Presumptive treatment with Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
Trial: NCT03731364
Drug: CA-008
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
Trial: NCT03731364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00125190
Drug: rhIGF-1 (mecasermin) for a period of 86 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day rhIGF-1 injections
Trial: NCT03927508
Drug: r-tPA
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse spray and infusion
Trial: NCT03780556
Drug: Lornoxicam and mepridine
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the effect of each to control pain
Trial: NCT00334932
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01771198
Drug: SIMVASTATIN
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SIMVASTATIN tablet of 40mg once a day during 30 days
Trial: NCT01934192
Drug: GSK962040 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
Trial: NCT01934192
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered IV every 6 hours
Trial: NCT01760824
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
Trial: NCT01760824
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
Trial: NCT03396250
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Trial: NCT01006863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
Trial: NCT04208763
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Trial: NCT00760838
Drug: Azithromycin 250 mg
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Trial: NCT00760838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Trial: NCT00915551
Drug: PEP005 (Ingenol Mebutate) gel, 0.015%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 3 consecutive days
Trial: NCT00915551
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 3 consecutive days
Trial: NCT02999633
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:pills Route of administration: oral
Trial: NCT03230916
Drug: IMI/REL FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Trial: NCT01697293
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01697293
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02075593
Drug: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
Trial: NCT02220972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00127504
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00929734
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg tablets, once daily in three months
Trial: NCT00929734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, once daily in three months
Trial: NCT02247505
Drug: Harnal-D Cap. 0.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247505
Drug: Cialis Tab. 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00548769
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
Trial: NCT00548769
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Trial: NCT00548769
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
Trial: NCT01253421
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose placebo capsule
Trial: NCT02711215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
Trial: NCT01525927
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for three cycles prior to radiotherapy
Trial: NCT04225208
Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Trial: NCT02579642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered with usual induction drugs for ECT
Trial: NCT01777919
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00206648
Drug: Betaferon/Betaseron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaseron 250 µg SC every other day
Trial: NCT00206648
Drug: Betaferon/Betaseron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex 30 µg IM once per week
Trial: NCT02648698
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
Trial: NCT06201182
Drug: Placebo via rectal enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via rectal enema
Trial: NCT06201182
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given twice daily for 2 consecutive days
Trial: NCT03844763
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX: 50 mg Daily untill PD or major toxicity
Trial: NCT03870763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02516618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00116805
Drug: TDF placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00116805
Drug: ADV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00116805
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Trial: NCT02740127
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
Trial: NCT01772433
Drug: Phonophoresis gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis with base gel for 10 days, daily
Trial: NCT03251287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral matching placebo
Trial: NCT00377234
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 3 months
Trial: NCT00492349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
Trial: NCT01495065
Drug: GSK2251052 750 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: 750 mg IV GSK2251052 single dose
Trial: NCT01495065
Drug: GSK2251052 1500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: 1500 mg IV GSK2251052 single dose
Trial: NCT01495065
Drug: GSK2251052 1500 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
Trial: NCT01495065
Drug: GSK2251052 2250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
Trial: NCT01495065
Drug: GSK2251052 3000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
Trial: NCT01495065
Drug: GSK2251052 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
Trial: NCT02156674
Drug: Naglazyme®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg per kg of body weight administered once weekly as an intravenous infusion
Trial: NCT03019536
Drug: LY3303560 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03019536
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03019536
Drug: Florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
Trial: NCT01490632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01989234
Drug: YKP10811
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01989234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00426517
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
Trial: NCT04255836
Drug: the first line chemotherapy for metastatic NSCLC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel+carboplatin or pemetrexed+cisplatin
Trial: NCT04387136
Drug: Sublingual Sufentanil
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
Trial: NCT00001165
Drug: combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00007904
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
Trial: NCT00007904
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients then receive doxorubicin IV on day 1.
Trial: NCT04480242
Drug: Inhaled Corticosteroids (ICs)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
Trial: NCT04480242
Drug: Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
Trial: NCT04480242
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
Trial: NCT00186056
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo tab
Trial: NCT01387568
Drug: saline Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
Trial: NCT02170805
Drug: BIBR 1048 MS capsule formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBR 1048 MS, formulation B 50 mg
Trial: NCT01313520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
Trial: NCT02175433
Drug: AGS67E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) infusion
Trial: NCT01919008
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00423085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Trial: NCT02365493
Drug: Beta-Lactam
RxNorm normalized name: Beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03370887
Drug: AZD8601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
Trial: NCT03370887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
Trial: NCT04046874
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Medication, imaging, referrals to other health services, other health care appointments
Trial: NCT00933231
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and Oral
Trial: NCT04357028
Drug: Measles-Mumps-Rubella Vaccine
RxNorm normalized name: MEASLES/MUMPS/RUBELLA VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles mumps Rubella vaccine is a weak attenuated life vaccine
Trial: NCT04357028
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Trial: NCT01968213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Trial: NCT00969033
Drug: CS-1008
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1008
Trial: NCT02105948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9% sodium chloride solution
Trial: NCT02576067
Drug: Low dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study participants will additionally receive 1 mg daily oral folate.
Trial: NCT02576067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01324492
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03500874
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1
Trial: NCT03500874
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
Trial: NCT03325712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet